ArticleJournal of sleep research2026
Nocturnal Hypoxemic Burden Predicts Mortality in Patients Awaiting Heart Transplantation.
Article in Journal of sleep research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03026634 (Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation - a Prospective Single Center Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation - a Prospective Single Center Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Risk stratification for patients with end-stage heart failure (HF) awaiting heart transplantation (HTX) is crucial. Sleep-disordered breathing (SDB) is a prevalent comorbidity, yet the impact of its resultant hypoxemic burden remains unclear in this population. We investigated the prognostic impact of nocturnal hypoxemic burden in patients with end-stage HF awaiting HTX. We prospectively enrolled 101 patients with end-stage HF listed for HTX at a single centre. Baseline polygraphy quantified nocturnal hypoxemic burden (time with SpO2 < 90%; t90). The primary endpoint was a 5-year composite of all-cause mortality or left ventricular assist device (LVAD) implantation. Multivariable Cox proportional hazards models were used for adjustment. During 5-year follow-up, 24 patients reached the primary endpoint. The primary finding was a significant, dose-response relationship between t90 (analysed as a continuous variable) and the primary endpoint (p < 0.001). In a multivariable Cox model adjusted for glomerular filtration rate (GFR) and left ventricular ejection fraction (LVEF), each 30-min increase in t90 was associated with a 29% increase in hazard (Adjusted HR: 1.29, 95% CI: 1.14-1.47, p < 0.001). A t90 of ≥ 180 min was identified as a clinical threshold of high risk, conferring a > 5-fold increase in hazard (Adjusted HR: 5.18, 95% CI: 1.69-15.81, p = 0.004). The cumulative duration of nocturnal hypoxemic burden is a powerful, independent predictor of death or LVAD implantation in patients with end-stage HF. Routine assessment of hypoxemic burden should be considered for risk stratification in patients awaiting heart transplantation. Trial Registration: ClinicalTrials.gov: NCT03026634.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.